Weight Loss Jabs Safe for Obese Teenagers, WHO Announces

**Lead**

The World Health Organization (WHO) has officially announced that weight loss injections, specifically glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide, are safe for use in obese teenagers. The landmark statement, released from WHO headquarters in Geneva, is expected to accelerate efforts by the National Health Service (NHS) to extend these therapies to younger patients in the United Kingdom, where childhood obesity rates remain stubbornly high.

**Contexto**

Obesity among adolescents has become a public health crisis across the developed world. In England alone, nearly one in four children leaving primary school is classified as overweight or obese, according to NHS Digital data. The WHO’s announcement follows a comprehensive review of clinical trials involving participants aged 12 to 17, including data from the STEP TEENS trial, which demonstrated that semaglutide leads to significant reductions in body mass index (BMI) when combined with lifestyle interventions.

GLP-1 receptor agonists work by mimicking a hormone that targets areas of the brain regulating appetite and food intake. While originally developed for type 2 diabetes management, their weight loss effects have led to widespread off-label use. The WHO’s endorsement specifically addresses safety concerns that had previously limited access for minors, including potential risks of pancreatitis, gallbladder issues, and thyroid C-cell tumours. The agency concluded that, under appropriate medical supervision, the benefits outweigh these rare risks for adolescents with a BMI above the 95th percentile.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) had already granted a licence for semaglutide use in teenagers, but uptake has been slow. Only a handful of NHS trusts currently offer the injections to under-18s, with eligibility largely restricted to specialist paediatric weight management clinics. The WHO’s global safety announcement is expected to standardise clinical protocols and encourage insurers and state health systems to expand coverage.

**Analise**

The significance of the WHO’s statement cannot be overstated. For the first time, a global health authority has given unequivocal backing to pharmacological intervention for adolescent obesity, shifting the paradigm from lifestyle-only approaches to a medicalised model. This places pressure on NICE (the National Institute for Health and Care Excellence) to review its current guidance, which has been criticised for being overly cautious. If NICE follows the WHO’s lead, tens of thousands of British teenagers could become eligible for weekly injections under NHS prescription, fundamentally altering paediatric obesity care.

However, the announcement also reignites a contentious debate about the medicalisation of childhood. Critics, including parent groups and some paediatric dieticians, argue that long-term safety data remain limited, spanning only a few years in most studies. There are concerns that teenagers might become dependent on the medication without addressing underlying behavioural or socioeconomic contributors to obesity. Furthermore, supply issues have plagued GLP-1 agonists globally, with shortages reported across the UK as adult demand surged. Prioritising adolescents could strain an already fragile supply chain.

From a technological standpoint, the WHO’s endorsement validates ongoing innovation in metabolic pharmacology. Drug companies are already racing to develop oral formulations and next-generation compounds with fewer side effects. The UK government, which recently announced a £40 million pilot for digital weight management tools, may now accelerate investment in integrated care pathways that combine pharmacotherapy with behavioural coaching and remote monitoring. This positions the United Kingdom as a potential test bed for the global rollout of adolescent weight loss therapies.

**Fontes**

World Health Organization official press release on GLP-1 safety update, published October 2026. NHS Digital data on childhood obesity prevalence. Medicines and Healthcare products Regulatory Agency (MHRA) licensing information for semaglutide in adolescents. STEP TEENS clinical trial results published in *The New England Journal of Medicine*. National Institute for Health and Care Excellence (NICE) guidelines on obesity management in children and young people.